SEK 13.3
(-1.48%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 53 Thousand SEK | 218.18% |
2022 | -11 Thousand SEK | 0.0% |
2021 | - SEK | 100.0% |
2020 | -31.73 Million SEK | -69.02% |
2019 | -18.77 Million SEK | -986289.74% |
2018 | -1903.30 SEK | 27.36% |
2017 | -2620.30 SEK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -12 Thousand SEK | -129.27% |
2024 Q3 | -3000.00 SEK | 75.0% |
2024 Q2 | -12 Thousand SEK | 0.0% |
2023 Q2 | - SEK | 100.0% |
2023 FY | 13 Thousand SEK | 218.18% |
2023 Q4 | 41 Thousand SEK | -59.8% |
2023 Q3 | 102 Thousand SEK | 0.0% |
2023 Q1 | -3000.00 SEK | 0.0% |
2022 Q3 | -3000.00 SEK | 40.0% |
2022 Q1 | - SEK | 0.0% |
2022 FY | -11 Thousand SEK | 0.0% |
2022 Q2 | -5000.00 SEK | 0.0% |
2022 Q4 | -3000.00 SEK | 0.0% |
2021 FY | - SEK | 100.0% |
2021 Q4 | - SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 Q2 | - SEK | 0.0% |
2021 Q1 | - SEK | 100.0% |
2020 FY | -31.73 Million SEK | -69.02% |
2020 Q4 | -12.79 Million SEK | -143.61% |
2020 Q3 | -5.25 Million SEK | 0.0% |
2019 FY | -18.77 Million SEK | -986289.74% |
2018 FY | -1903.30 SEK | 27.36% |
2017 FY | -2620.30 SEK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Alligator Bioscience AB (publ) | -160.68 Million SEK | 100.033% |
Ziccum AB (publ) | -23.28 Million SEK | 100.228% |
Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
BioArctic AB (publ) | 346.31 Million SEK | 99.985% |
Sprint Bioscience AB (publ) | 41.78 Million SEK | 99.873% |
Mendus AB (publ) | 28.48 Million SEK | 99.814% |
Genovis AB (publ.) | 54 Million SEK | 99.902% |
Intervacc AB (publ) | -13.79 Million SEK | 100.384% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 97.559% |
Active Biotech AB (publ) | -1.67 Million SEK | 103.164% |
Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 99.468% |
Bio-Works Technologies AB (publ) | 26.82 Million SEK | 99.802% |
Aptahem AB (publ) | 2.63 Million SEK | 97.985% |
Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 101.549% |
Kancera AB (publ) | -1.96 Million SEK | 102.697% |
Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 31.169% |
Fluicell AB (publ) | 1.73 Million SEK | 96.951% |
Saniona AB (publ) | 11.78 Million SEK | 99.55% |
Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 101.036% |
Biovica International AB (publ) | 6.87 Million SEK | 99.229% |
Spago Nanomedical AB (publ) | -23.28 Million SEK | 100.228% |
AcouSort AB (publ) | 8.38 Million SEK | 99.368% |
Xintela AB (publ) | 78 Thousand SEK | 32.051% |
Abliva AB (publ) | -35.66 Million SEK | 100.149% |
Egetis Therapeutics AB (publ) | -146.9 Million SEK | 100.036% |
Karolinska Development AB (publ) | 2.8 Million SEK | 98.112% |
OncoZenge AB (publ) | 3000.00 SEK | -1666.667% |
Amniotics AB (publ) | -1.93 Million SEK | 102.746% |
2cureX AB (publ) | -37.48 Million SEK | 100.141% |
CombiGene AB (publ) | -21.29 Million SEK | 100.249% |
Asarina Pharma AB (publ) | -423 Thousand SEK | 112.53% |
Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.995% |
Camurus AB (publ) | 1.58 Billion SEK | 99.997% |
Corline Biomedical AB | 28.38 Million SEK | 99.813% |
IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 100.043% |
Isofol Medical AB (publ) | -34.41 Million SEK | 100.154% |
I-Tech AB | 27.56 Million SEK | 99.808% |
Hansa Biopharma AB (publ) | 70.95 Million SEK | 99.925% |
Cyxone AB (publ) | 2.61 Million SEK | 97.97% |
ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 98.443% |
Biosergen AB | -456 Thousand SEK | 111.623% |
Cantargia AB (publ) | -3.45 Million SEK | 101.536% |
NextCell Pharma AB | -43.74 Million SEK | 100.121% |
Xspray Pharma AB (publ) | -9.19 Million SEK | 100.576% |
Elicera Therapeutics AB (publ) | 11.21 Million SEK | 99.528% |
Nanologica AB (publ) | -76 Thousand SEK | 169.737% |
SynAct Pharma AB | -778 Thousand SEK | 106.812% |
Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 127.461% |
Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
LIDDS AB (publ) | -12.92 Million SEK | 100.41% |
BioInvent International AB (publ) | 71.46 Million SEK | 99.926% |
Alzinova AB (publ) | 19.87 Million SEK | 99.733% |
Oncopeptides AB (publ) | 36.29 Million SEK | 99.854% |
Pila Pharma AB (publ) | 1.46 Million SEK | 96.377% |
Guard Therapeutics International AB (publ) | -15 Thousand SEK | 453.333% |
Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 96.803% |
Simris Alg AB (publ) | 2 Million SEK | 97.359% |
Diamyd Medical AB (publ) | -3.58 Million SEK | 101.48% |
Xbrane Biopharma AB (publ) | 35.38 Million SEK | 99.85% |
Ascelia Pharma AB (publ) | -1.04 Million SEK | 105.052% |
Diagonal Bio AB (publ) | 3.13 Million SEK | 98.308% |